Journal
CLINICAL & TRANSLATIONAL ONCOLOGY
Volume 22, Issue 7, Pages 989-1003Publisher
SPRINGER INT PUBL AG
DOI: 10.1007/s12094-019-02218-4
Keywords
ALK; Biomarkers; Non-small-cell lung cancer; EGFR; BRAF; PD-L1; ROS1
Categories
Ask authors/readers for more resources
In 2011 the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) started a joint project to establish guidelines on biomarker testing in patients with advanced non-small-cell lung cancer (NSCLC) based on current evidence. As this field is constantly evolving, these guidelines have been updated, previously in 2012 and 2015 and now in 2019. Current evidence suggests that the mandatory tests to conduct in all patients with advanced NSCLC are forEGFRandBRAFmutations,ALKandROS1rearrangements and PD-L1 expression. The growing need to study other emerging biomarkers has promoted the routine use of massive sequencing (next-generation sequencing, NGS). The coordination of every professional involved and the prioritisation of the most suitable tests and technologies for each case remains a challenge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available